MedPage Today November 15, 2024
Katherine Kahn

— New research focuses on interventions for highest-risk patients

Although the general population now has at least some immunity against COVID-19, the consequences of severe disease are frequently overlooked for certain patient populations, such as those with comorbidities or immune compromise. However, new research into COVID prophylaxis and therapeutics offers some hope that novel treatments may be on the horizon.

Is Paxlovid Still Useful?

The original phase II/III EPIC-HR trial showed that nirmatrelvir/ritonavir (Paxlovid) was nearly 89% effective for preventing COVID hospitalization and all-cause death in unvaccinated high-risk patients.

“These were remarkable findings, but this trial was conducted early on in the pandemic among unvaccinated high-risk patients and the applicability of these findings to current settings of high population immunity...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health / COVID
Related Articles:
Respiratory illnesses surge: 5 updates
How America Lost Control of the Bird Flu, Setting the Stage for Another Pandemic
Long COVID Symptoms Improve With Outpatient Intervention
Science magazine names HIV drug its 'Breakthrough of the Year'
Integrating Equity Into Licensing Agreements For Taxpayer-Funded Technologies

Share This Article